Within PD, changing phosphoinositide levels could potentially be mediated by the aforementioned α-synuclein inhibition of PI(4,5)P2 degrading PLC enzymes, as well as upregulation of the PI(3,4,5)P3 degradation enzyme PTEN. The gene discussed is HSPG2; the disease is Parkinson disease.